Literature DB >> 18200333

Gateways to clinical trials.

M Bayés1, X Rabasseda, J R Prous.   

Abstract

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Intergrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 249553, 2-Methoxyestradiol; Abatacept, Adalimumab, Adefovir dipivoxil, Agalsidase beta, Albinterferon alfa-2b, Aliskiren fumarate, Alovudine, Amdoxovir, Amlodipine besylate/atorvastatin calcium, Amrubicin hydrochloride, Anakinra, AQ-13, Aripiprazole, AS-1404, Asoprisnil, Atacicept, Atrasentan; Belimumab, Bevacizumab, Bortezomib, Bosentan, Botulinum toxin type B, Brivaracetam; Catumaxomab, Cediranib, Cetuximab, cG250, Ciclesonide, Cinacalcet hydrochloride, Curcumin, Cypher; Darbepoetin alfa, Denosumab, Dihydrexidine; Eicosapentaenoic acid/docosahexaenoic acid, Entecavir, Erlotinib hydrochloride, Escitalopram oxalate, Etoricoxib, Everolimus, Ezetimibe; Febuxostat, Fenspiride hydrochloride, Fondaparinux sodium; Gefitinib, Ghrelin (human), GSK-1562902A; HSV-tk/GCV; Iclaprim, Imatinib mesylate, Imexon, Indacaterol, Insulinotropin, ISIS-112989; L-Alanosine, Lapatinib ditosylate, Laropiprant; Methoxy polyethylene glycol-epoetin-beta, Mipomersen sodium, Motexafin gadolinium; Natalizumab, Nimotuzumab; OSC, Ozarelix; PACAP-38, Paclitaxel nanoparticles, Parathyroid Hormone-Related Protein-(1-36), Pasireotide, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Pemetrexed disodium, Pertuzumab, Picoplatin, Pimecrolimus, Pitavastatin calcium, Plitidepsin; Ranelic acid distrontium salt, Ranolazine, Recombinant human relaxin H2, Regadenoson, RFB4(dsFv)-PE38, RO-3300074, Rosuvastatin calcium; SIR-Spheres, Solifenacin succinate, Sorafenib, Sunitinib malate; Tadalafil, Talabostat, Taribavirin hydrochloride, Taxus, Temsirolimus, Teriparatide, Tiotropium bromide, Tipifarnib, Tirapazamine, Tocilizumab; UCN-01, Ularitide, Uracil, Ustekinumab; V-260, Vandetanib, Vatalanib succinate, Vernakalant hydrochloride, Vorinostat; YM-155; Zileuton, Zoledronic acid monohydrate.

Entities:  

Mesh:

Year:  2007        PMID: 18200333

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  6 in total

Review 1.  Carbapenems: past, present, and future.

Authors:  Krisztina M Papp-Wallace; Andrea Endimiani; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

Review 2.  [The basics of phosphodiesterase type 5 (PDE5) inhibition in urology].

Authors:  A J Becker; S Uckert; C G Stief
Journal:  Urologe A       Date:  2008-12       Impact factor: 0.639

3.  In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice.

Authors:  Ghazal Zekavat; Susan Y Rostami; Armen Badkerhanian; Ronald F Parsons; Brigitte Koeberlein; Ming Yu; Christopher D Ward; Thi-Sau Migone; Liping Yu; George S Eisenbarth; Michael P Cancro; Ali Naji; Hooman Noorchashm
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

4.  The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.

Authors:  Lei Zhao; Qiao-Qiao Li; Rui Zhang; Mian Xi; Yi-Ji Liao; Dong Qian; Li-Ru He; Yi-Xin Zeng; Dan Xie; Meng-Zhong Liu
Journal:  Tumour Biol       Date:  2012-03-03

5.  Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.

Authors:  Lei Zhao; Li-Ru He; Mian Xi; Mu-Yan Cai; Jing-Xian Shen; Qiao-Qiao Li; Yi-Ji Liao; Dong Qian; Zi-Zhen Feng; Yi-Xin Zeng; Dan Xie; Meng-Zhong Liu
Journal:  J Transl Med       Date:  2012-12-11       Impact factor: 5.531

6.  Oxidative stress induced by carboplatin promotes apoptosis and inhibits migration of HN-3 cells.

Authors:  Pei-Jie He; Rui-Feng Ge; Wen-Jing Mao; Phil-Sang Chung; Jin-Chul Ahn; Hai-Tao Wu
Journal:  Oncol Lett       Date:  2018-10-10       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.